Stiebel-Kalish Hadas, Kalish Yuval, Bar-On Ruth Huna, Setton Avi, Niimi Yasu, Berenstein Alejandro, Kupersmith Mark J
Neuro-Ophthalmology Service, Rabin Medical Center, Petah Tikva, Israel.
Neurosurgery. 2005 Nov;57(5):850-7; discussion 850-7. doi: 10.1227/01.neu.0000179922.48165.42.
We present the largest reported cohort of carotid cavernous aneurysms (CCA), comparing the neuro-ophthalmic presentation, complications, and outcome with and without endovascular treatment.
Retrospective review of 185 patients with 206 CCAs examined between 1980 and 2001 at a tertiary neuro-ophthalmology and neurovascular service. Patients' symptoms and findings at presentation were recorded and compared with those at outcome. The effect of treatment on outcome and on complication rate was analyzed using the chi test, multivariate analysis of covariance, model-selection log-linear analysis, and multinomial logistic regression.
Long-term follow-up was available for 189 of 206 CCAs. Seventy-four CCAs underwent treatment (endovascular, 67 [91%]; surgical treatment, 6 [9%]), and 115 were followed for an average of 4 years, two of which required later treatment. Treatment reduced the incidence and severity of pain, even after adjusting for the severity of initial pain (F(1,192 = 9.59, P = 0.002). Treatment did not significantly affect the patient's final diplopia after adjusting for their initial diplopia (F(1, 182 = 2.01, P = 0.158). Statistical examination revealed that the treated group had a higher proportion of neurological and visual complications than people who were not treated (2(2). = 25.26, P = 0.0003).
Endovascular treatment of carotid cavernous aneurysms leads to a significantly higher rate of pain resolution compared with untreated patients, even after adjusting for initial pain severity. Diplopia may not resolve after treatment. The results of this study underscore our approach indicating treatment only in cases of debilitating pain, visual loss from compression, or diplopia in primary gaze or in patients with risk factors for major complications such as pre-existing coagulopathy or sphenoid sinus erosion.
我们展示了已报道的最大队列的海绵窦段颈内动脉瘤(CCA),比较了接受和未接受血管内治疗的患者的神经眼科表现、并发症及预后。
对1980年至2001年间在一家三级神经眼科和神经血管科就诊的185例患有206个CCA的患者进行回顾性研究。记录患者就诊时的症状和检查结果,并与预后情况进行比较。使用卡方检验、协方差多变量分析、模型选择对数线性分析和多项逻辑回归分析治疗对预后和并发症发生率的影响。
206个CCA中有189个获得了长期随访。74个CCA接受了治疗(血管内治疗67个[91%];手术治疗6个[9%]),115个未接受治疗的患者平均随访4年,其中2个后来需要治疗。即使在对初始疼痛的严重程度进行校正后,治疗仍降低了疼痛的发生率和严重程度(F(1,192)=9.59,P=0.002)。在对初始复视进行校正后,治疗对患者最终的复视没有显著影响(F(1,182)=2.01,P=0.158)。统计检验显示,治疗组的神经和视觉并发症比例高于未治疗组(χ²(2)=25.26,P=0.0003)。
与未治疗的患者相比,海绵窦段颈内动脉瘤的血管内治疗即使在对初始疼痛严重程度进行校正后,也能显著提高疼痛缓解率。治疗后复视可能无法缓解。本研究结果强调了我们的治疗方法,即仅在出现使人衰弱的疼痛、因压迫导致视力丧失、原始终视时出现复视或存在诸如既往凝血病或蝶窦侵蚀等主要并发症危险因素的患者中进行治疗。